What are the side effects of Abilify (aripiprazole)?

Abilify Side Effects

Abilify (aripiprazole) carries a range of side effects that require careful monitoring, with the most serious being neuroleptic malignant syndrome, tardive dyskinesia, metabolic disturbances, and unusual impulsive-compulsive behaviors that can significantly impact quality of life. 1

Serious and Life-Threatening Side Effects

Neuroleptic Malignant Syndrome (NMS)

This rare but potentially fatal condition presents with:

• High fever
• Severe muscle rigidity
• Confusion
• Profuse sweating
• Changes in pulse, heart rate, and blood pressure

Immediate medical attention is required if these symptoms develop. 1

Tardive Dyskinesia

Uncontrolled movements affecting the face, tongue, or other body parts may develop and can be permanent even after stopping Abilify. This risk increases with duration of treatment and total cumulative dose. 1

Metabolic Complications

Monitor closely for metabolic side effects that directly impact morbidity and mortality:

• Hyperglycemia and diabetes: Can progress to coma or death if severe. Check blood sugar before starting and regularly during treatment, especially in patients with diabetes risk factors (obesity, family history). 1
• Dyslipidemia: Increased cholesterol and triglycerides require regular monitoring 1
• Weight gain: Check weight regularly, though aripiprazole carries lower risk compared to other antipsychotics 2

Monitoring schedule per 2025 INTEGRATE guidelines: BMI, waist circumference, and blood pressure weekly for 6 weeks, then at 3 months, then annually. Fasting glucose at baseline, 4 weeks, 3 months, then annually. 2

Impulsive-Compulsive Behaviors

A particularly concerning side effect that severely impacts quality of life includes:

• Pathological gambling
• Compulsive sexual urges
• Binge eating or uncontrollable eating
• Compulsive shopping
• Kleptomania
• Trichotillomania

These behaviors typically emerge within 30 days of starting aripiprazole (average dose 11.63 mg/day) and resolve within 30 days of discontinuation or dose reduction. They occur in both patients with and without prior history of these behaviors. Educate patients and families about these risks at treatment initiation. 1, 3

Common Side Effects in Adults

The most frequently reported adverse effects include:

• Nausea, vomiting, constipation
• Headache
• Blurred vision
• Dizziness
• Anxiety and insomnia
• Akathisia (inner restlessness/need to move) - manageable with dose reduction or adjunctive propranolol (10-30 mg, 2-3 times daily) 2, 1
• Upper respiratory illness 1

Common Side Effects in Children and Adolescents

Pediatric patients experience a distinct side effect profile:

• Somnolence (most common)
• Headache and fatigue
• Increased or decreased appetite
• Increased salivation/drooling
• Weight gain
• Uncontrolled movements (restlessness, tremor, muscle stiffness)
• Insomnia

Severe adverse events in children include neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior, warranting heightened vigilance in this vulnerable population. 4

Cardiovascular Effects

• Orthostatic hypotension: Lightheadedness or fainting when rising from sitting/lying position
• Falls risk: Due to sedation, dizziness, and blood pressure changes - particularly concerning for elderly patients
• Stroke risk: Increased in elderly patients with dementia-related psychosis (Abilify is NOT approved for this population) 1

Neurological Effects

• Seizures: Monitor patients with seizure history
• Difficulty swallowing: Can lead to aspiration pneumonia 1
• Parkinsonian side effects (though less common than with typical antipsychotics) 5

Hematologic Effects

• Low white blood cell count: Requires monitoring, especially in patients with history of leukopenia 1

Hyperprolactinemia Management

Notably, aripiprazole as a D2 partial agonist can actually reduce prolactin levels when used adjunctively with other antipsychotics that cause hyperprolactinemia. This represents a beneficial effect when managing prolactin-related side effects from other medications. 2

Temperature Regulation

Impaired ability to regulate body temperature, especially during:

• Strenuous exercise
• Exposure to extreme heat

Ensure adequate hydration to prevent dehydration. 1

Clinical Monitoring Pitfalls

Common mistakes to avoid:

• Failing to check fasting glucose at 4 weeks post-initiation (critical window for detecting metabolic changes)
• Not educating patients about impulsive-compulsive behaviors before starting treatment
• Overlooking akathisia as a cause of apparent anxiety or agitation
• Inadequate monitoring of weight and metabolic parameters in the first 6 weeks
• Missing early signs of tardive dyskinesia by not performing regular movement assessments

Relative Safety Profile

Aripiprazole demonstrates advantages over other antipsychotics in several domains:

• Lower risk of metabolic syndrome compared to olanzapine and quetiapine 6
• Minimal prolactin elevation 7
• No significant QTc prolongation 7
• Lower weight gain risk compared to other second-generation antipsychotics 6

However, when used in polypharmacy, side effect burden increases, including higher rates of sedation, hypersalivation, sexual dysfunction, and cognitive impairment. 5